Answers are grounded in this paper and cite their sources.
Case report demonstrates leukocytoclastic vasculitis with purpura in a metastatic colorectal cancer patient receiving panitumumab, highlighting a rare cutaneous adverse reaction.
Introduction. Panitumumab is a fully human monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR). It is used in the treatment of metastatic colorectal cancer (mCRC) in patients with RAS wild-type tumors. Dermatological toxicities occur in approximately 90% of patients receiving panitumumab, with severe cases reported in 15% of patients. In rare instances, severe vasculitis has also been associated with its use. Case report. A 51-year-old male patient with metastatic colorectal cancer and KRAS wild-type status presented with palpable purpura and petechiae. Ten days after receiving five cycles of FOLFOX in combination with panitumumab, the patient developed purpuric lesions on both lower extremities. A skin biopsy of these lesions confirmed a diagnosis of leukocytoclastic vasculitis. During the sixth treatment cycle, panitumumab was withheld, and the patient received only mFOLFOX-6, leading to lesion regression. Panitumumab-induced leukocytoclastic vasculitis was considered as the likely cause. Discussion. This case is notable as petechiae and purpura are rare dermatological toxicities associated with panitumumab. A definitive diagnosis of leukocytoclastic vasculitis was confirmed through skin biopsy. The lesions responded well to oral corticosteroids and topical treatment, leading to resolution. Subsequently, the patient’s metastatic colorectal cancer treatment continued without panitumumab.
No takes yet. Share an insight, caveat, or question.
Yıldız et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: